Advertisement

Topics

Hutchison China MediTech (Chi-Med) And AstraZeneca PLC Initiate SAVOIR, A Global Phase III Trial Of Savolitinib In Papillary Renal Cell Carcinoma

20:00 EDT 28 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Hutchison China MediTech (Chi-Med) And AstraZeneca PLC Initiate SAVOIR, A Global Phase III Trial Of Savolitinib In Papillary Renal Cell Carcinoma

NEXT ARTICLE

More From BioPortfolio on "Hutchison China MediTech (Chi-Med) And AstraZeneca PLC Initiate SAVOIR, A Global Phase III Trial Of Savolitinib In Papillary Renal Cell Carcinoma"

Advertisement
Quick Search
Advertisement
Advertisement